2026 ICD-10-CM Diagnosis Code C92.51Acute myelomonocytic leukemia, in remission

ICD-10-CM Codes›C00–D49›C81-C96›C92

ICD-10-CM C92.51
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

C92.51 is a billable ICD-10-CM diagnosis code for acute myelomonocytic leukemia, in remission. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 820 through 822, 834 through 839. Coders also document this condition as acute myeloid leukemia in remission. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Leukemia in remission.

Code Identity

ICD-10-CM Code
C92.51
Billable Status
Yes — Valid for Submission
Code Describes
Acute myelomonocytic leukemia, in remission
Short Description
Acute myelomonocytic leukemia, in remission
Same as the full description in the CMS dataset.
Parent Code
C92.5
Acute myelomonocytic leukemia

Code Classification

ChapterC00–D49Neoplasms
SectionC81-C96Malignant neoplasms of lymphoid, hematopoietic and related tissue
CategoryC92Myeloid leukemia
This CodeC92.51Acute myelomonocytic leukemia, in remission

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Acute myeloid leukemia in remission
  • Acute myelomonocytic leukemia, FAB M4
  • Acute myelomonocytic leukemia, FAB M4, in remission
  • Myeloid leukemia in remission
  • Myelomonocytic leukemia

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NEO075
Leukemia in remission
Default principal diagnosis: inpatient Yes · outpatient Yes

Patient EducationClinical

Acute Myeloid Leukemia

Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone marrow. Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. Each type of cell has a different job:

The full article covers:

  • What is leukemia?
  • What is acute myeloid leukemia (AML)?
  • What causes acute myeloid leukemia (AML)?
  • Who is at risk for acute myeloid leukemia (AML)?
  • What are the symptoms of acute myeloid leukemia (AML)?
  • How is acute myeloid leukemia (AML) diagnosed?
  • What are the treatments for acute myeloid leukemia (AML)?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert C92.51 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
205.01 Act myl leuk w rmsion
Approximate The match is approximate rather than exact.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About C92.51Overview

Is C92.51 (Acute myelomonocytic leukemia) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report acute myelomonocytic leukemia, in remission on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does C92.51 group to?

When acute myelomonocytic leukemia, in remission is the principal diagnosis on an inpatient stay, it groups to MS-DRG 820, 821, 822, 834, 835, 836, 837, 838, 839, with relative weights from 1.2040 to 5.8648 depending on complications. Higher weights mean higher Medicare reimbursement.

What is the ICD-9 equivalent of C92.51?

Under the General Equivalence Mappings, acute myelomonocytic leukemia, in remission converts to ICD-9-CM 205.01 (act myl leuk w rmsion). The mapping is approximate, so confirm the match fits the documentation.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.